Assessment of bone turnover markers and bone mineral density in normal short boys

Aydın, Zeynep Gökçe Gayretli; Bideci, Aysun; Emeksiz, Hamdi Cihan; Çelik, Nurullah; Döğer, Esra; Bukan, Neslihan; Yιldιz, Ümmügülsüm; Çamurdan, Orhun; Cinaz, Peyami

doi:10.1515/jpem-2014-0099

Cited by 5 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hence, the presence of VF may be a major indicator of height loss. Because of the continuous bone growth in children, reduced height growth induced by VF could impair the elongation of growth and puberty and the attainment of peak bone mass ( 19 ). According to Suenobu et al, the critical point of reduced height velocity was during the interval between pretreatment and maintenance therapy, while height recovery was detected from the beginning of maintenance therapy until the end of treatment ( 20 ).…”

Section: Discussionmentioning

confidence: 99%

Effect of Vertebral Fracture on Auxological Profiles of Children Undergoing Acute Lymphoblastic Leukemia Treatment

et al. 2021

View full text Add to dashboard Cite

Background: Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy, and children with ALL often experience skeletal morbidity such as vertebral fractures (VF) during and after ALL treatment. Among various treatment-associated factors that affect growth pattern, the presence of VF might trigger growth impairment.Objective: This study aimed to investigate the overall VF incidence following childhood ALL treatment and examined the association of VF with growth.Methods: Children diagnosed with ALL whose treatment was completed between 2 and 15 years of age and who were screened with lateral thoracolumbar spine radiographs were enrolled. Clinical data, including anthropometric parameters were obtained at leukemia diagnosis (LD), treatment completion (TC), and 12 months following TC while VF assessment were obtained at TC and 12 months following TC.Results: In total, 155 children were included, and height status was decreased, whereas weight and BMI status were increased throughout three observational points. VF incidence at TC was 18.7%. Height status were lower in children with VF at LD, TC, and 12 months following TC, while a greater height decline was observed during the treatment period. Age and height status at LD and average glucocorticoid (GC) dose were associated VF incidence at TC. The presence of VF was a significant risk factor of height decline during the treatment period.Conclusion: A substantial number of children experienced VF following ALL treatment completion, and the presence of VF might adversely affect auxological status in children. VF detection by routine surveillance throughout childhood ALL treatment is recommended to try to prevent compromised growth.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of Vertebral Fracture on Auxological Profiles of Children Undergoing Acute Lymphoblastic Leukemia Treatment

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Nevertheless, in a study of bone turnover markers in males with CDGP, values remained in the normal range for references based on pubertal stage (99). Another study compared bone turnover markers in children with CDGP, familial short stature, and typically developing boys and found a difference only in the urinary deoxypyridinoline levels (100). Moirera-Andres et al opined that finding decreased prepubertal mineralization in children with CDGP might suggest an inherent predisposition to osteopenia, rather than a later function of sex steroid exposure delay (101).…”

Section: Constitutional Delay Of Growth and Pubertymentioning

confidence: 99%

Transition of young adults with metabolic bone diseases to adult care

Ross

Bowden

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

As more accurate diagnostic tools and targeted therapies become increasingly available for pediatric metabolic bone diseases, affected children have a better prognosis and significantly longer lifespan. With this potential for fulfilling lives as adults comes the need for dedicated transition and intentional care of these patients as adults. Much work has gone into improving the transitions of medically fragile children into adulthood, encompassing endocrinologic conditions like type 1 diabetes mellitus and congenital adrenal hyperplasia. However, there are gaps in the literature regarding similar guidance concerning metabolic bone conditions. This article intends to provide a brief review of research and guidelines for transitions of care more generally, followed by a more detailed treatment of bone disorders specifically. Considerations for such transitions include final adult height, fertility, fetal risk, heritability, and access to appropriately identified specialists. A nutrient-dense diet, optimal mobility, and adequate vitamin D stores are protective factors for these conditions. Primary bone disorders include hypophosphatasia, X-linked hypophosphatemic rickets, and osteogenesis imperfecta. Metabolic bone disease can also develop secondarily as a sequela of such diverse exposures as hypogonadism, a history of eating disorder, and cancer treatment. This article synthesizes research by experts of these specific disorders to describe what is known in this field of transition medicine for metabolic bone diseases as well as unanswered questions. The long-term objective is to develop and implement strategies for successful transitions for all patients affected by these various conditions.

show abstract

“…Тем не менее значительно более высокие уровни дезоксипиридинолина в моче по сравнению с семейнoй низкорослостью и контро льными группами могут быть показателем более позднего развития остеопороза. Таким образом, для лучшего понимания костнoгo метаболизма у этих пациентов необходимы долгосрочные последующие исследования с мониторингом минерального состояния костей у препубертатных мальчиков с КЗРП от препубертатного периода до зрелого возраста [15].…”

Section: клиникаunclassified

Конституціональна Затримка Росту І Пубертату У Хлопчиків: Огляд Літератури

Grossman

Ismailov²,

Kulmirzayeva³

et al. 2021

Mìžnarodnij endokrinologìčnij žurnal

View full text Add to dashboard Cite

Резюме. Oбзор сфокусирован на диагностике, клиническом и общем терапевтическом подходе к конституциональной задержке роста и полового созревания и гипогонадотрофическому гипогонадизму у мужчин, которые трудно различить. Клинический анамнез и физикальное обследование должны быть тщательно выполнены. Задержка полового развития обусловлена конституциональной задержкой роста и полового созревания у подавляющего большинства детей. Ее следует отличать от гипогонадизма-патологического состояния-у небольшой доли мальчиков. Ряд лабораторных тестов позволяет прогнозировать наступление и прогрессирование полового созревания. Тем не менее появление высокочувствительных систем иммуноанализа и радиометрического иммуноанализа для лютеинизирующего гормона, фолликулостимулирующего гормона и тестостерона не решило проблему полностью, поскольку их значения могут перекрываться между нормальными и патологическими состояниями.

show abstract

Assessment of bone turnover markers and bone mineral density in normal short boys

Cited by 5 publications

References 28 publications

Effect of Vertebral Fracture on Auxological Profiles of Children Undergoing Acute Lymphoblastic Leukemia Treatment

Effect of Vertebral Fracture on Auxological Profiles of Children Undergoing Acute Lymphoblastic Leukemia Treatment

Transition of young adults with metabolic bone diseases to adult care

Конституціональна Затримка Росту І Пубертату У Хлопчиків: Огляд Літератури

Contact Info

Product

Resources

About